About Amunix
Amunix is a Healthcare company based in Mountain View (United States) founded in 2006, and was acquired by Sanofi in December 2021. Peptide-based therapeutics are developed for cancers and immune disorders. Amunix has raised $200.59 million across 9 funding rounds from investors including BlackRock, Bain Capital and Franklin Templeton. The company has 82 employees. Its focus areas include Life Sciences, Immunology, Drugs and Diversified. Its legal entity is AMUNIX OPERATING INC. Its competitors include Moderna, BeiGene and Biogen; 3 of its 3 listed competitors have raised funding.
Company details
Developer of peptide-based therapeutics. The lead candidate AMX-818 is a masked T cell engager targeting HER2, a receptor tyrosine kinase expressed on a wide variety of solid tumors, others include Wave2 XPAT, Wve3 XPAT, IL12 XPAC, and others for immune disorders and cancers. The companys products are based on its proprietary XTEN half-life extension, XDC drug-conjugate delivery, and ProTIA pro-drug, bispecific T cell engager platform.
- Headquarters Mountain View, United States
- Employees 82
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website amunix.com
- Social LinkedIn
- Acquired by Sanofi (Dec 2021)
- Legal Name Amunix Operating Inc.
Funding Insights of Amunix
Amunix has successfully raised a total of $200.59M across 9 strategic funding rounds. The most recent funding activity was a Series B round of $117 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $200.59M
- Total Rounds 9
- Last Round Series B — $117M
- First Round $1.01M
(Apr 2007)
- Investors Count 18
All 9 funding rounds of Amunix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2021 | $117M | Series B | – | Viking Global Investors | |
| Mar 2020 | $83.59M | Series A | – | Omega Funds | |
| Jun 2018 | Series A | – | Frazier Healthcare Partners | – | |
| Aug 2012 | $157,550 | Grant | – | – | |
| Aug 2009 | $995,124 | Grant | – | – | |
| Sep 2008 | $995,124 | Grant | – | – | |
| Aug 2008 | $1.01M | Grant | – | – | |
| Sep 2007 | $995,124 | Grant | – | – | |
| Apr 2007 | $1.01M | Grant | – | – |
19 investors in total: 19 institutional.
Investors in Amunix
Amunix has secured backing from 19 investors, including venture fund and institutional investors. Prominent investors backing the company include BlackRock, Bain Capital and Franklin Templeton.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private investment firm focused on multiple sectors | vikingglobal.com | Greenwich, United States | ||
Debt and equity investments are pursued across multiple sectors. | 1984 | baincapital.com | Boston, United States | |
Multiple sectors are targeted for venture capital investments. | 1934 | janushenderson.com | London, United Kingdom | |
Venture capital firm | omegafunds.com | Boston, United States | ||
Healthcare sector private equity investments are managed by the firm. | 1991 | frazierhealthcare.com | Seattle, United States | |
Private equity firm focused on life science sector | longitudecapital.com | Menlo Park, United States | ||
Investing in Life Sciences sectors like Healthcare and Biotechnology. | casdincapital.com | |||
Venture capital firm focused on tech sectors | venrock.com | Palo Alto, United States | ||
US focused venture capital firm | polarispartners.com | Boston, United States | ||
Two River is engaged in building life science companies. | tworiver.com | New York, United States |
Investor details for Amunix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Amunix
43 people are tracked at Amunix (18 in leadership, 25 in team); the tracked headcount is 82.
| Name | Role | Group |
|---|---|---|
Brianna Mbow | Sr. Director, Head Of Development Project Management | Leadership |
Tracy Young, PhD | Director, Protein Engineering | Leadership |
Bee-Cheng Sim | Director to Vice President, Discovery Biology & Preclinical Development | Leadership |
Lucas Liu | Director, Protein Sciences | Leadership |
Michael Fox | Associate Director, Bioanalytical Sciences | Leadership |
Mikhail Hammond | Director, Bioanalytical Sciences | Leadership |
Mark McCleland | Global Project Head And Head Of Clinical Translational Development | Leadership |
Maria Bagniewska, PhD | Head of Portfolio Management and Operations, Sanofi Portfolio Innovation and Excellence | Leadership |
Mika Derynck | Chief Medical Officer | Leadership |
Shanrong Zhao | Vice President, Head of Bioinformatics, Data Analytics and Library Design | Leadership |
Sandy Deveze | Head of Clinical Data Management | Leadership |
Carlos Pantoja, MD, PhD | Medical Director, Clinical Development | Leadership |
Paul Hudson | CEO, Sanofi | Leadership |
Mika Kakefuda Derynck | Chief Medical Officer | Leadership |
Bryan Irving | Chief Scientific Officer | Leadership |
Volker Schellenberger | CTO | Leadership |
AiPing [Michelle] Lee | Associate Director | Project & Program Management | Leadership |
Maninder Hora | Chief Technical Operations Officer | Leadership |
Kapo B. | Senior Manager Global Project Manager | Team |
Bianca Reyes | Research Associate, Bioanalytical Sciences | Team |
23 more people are available in the full profile.
Complete people profiles for Amunix
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Amunix
4 dated milestones of Amunix across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Amunix is founded.
- Funding First funding round of $1.0M.
- Funding Latest funding round, Series B, of $117.0M.
- Exit Acquired by Sanofi.
Competitors of Amunix
Amunix has 3 listed competitors in our database, 3 of them funded. They include Moderna, BeiGene and Biogen.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. |
Detailed competitors of Amunix
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Amunix (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Amunix
Complete news archive for Amunix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Amunix
Amunix was founded in 2006 and raised its 1st funding round 1 year after it was founded.
Amunix is headquartered in Mountain View, United States. It is registered at Mountain View, California, United States.
Amunix is a funded company, having raised a total of $200.59M across 9 funding rounds to date. The company's 1st funding round was a Grant of $1.01M, raised on Apr 2007.
Amunix has 82 employees.
Developer of peptide-based therapeutics. The lead candidate AMX-818 is a masked T cell engager targeting HER2, a receptor tyrosine kinase expressed on a wide variety of solid tumors, others include Wave2 XPAT, Wve3 XPAT, IL12 XPAC, and others for immune disorders and cancers. The companys products are based on its proprietary XTEN half-life extension, XDC drug-conjugate delivery, and ProTIA pro-drug, bispecific T cell engager platform.
Amunix has 19 investors. Key investors include BlackRock, Bain Capital, Franklin Templeton, Sanofi, and HHS.
Amunix operates through Amunix Operating Inc..
Yes. Amunix was acquired by Sanofi in December 2021.